The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of BREAKING: The FDA just reversed their 2023 peptide ban. 12 peptides pulled from the Category 2 restricted list: 1. BPC 157 2. Thymosin beta 4 fragment (TB 500) 3. Epitalon 4. GHK Cu 5. MOTS C 6. FDA considers adding a dozen peptides to its bulk drug compounding list RAPS When will the FDA reclassify BPC 157 to Category 1 Octagon AI